Primary prevention of COVID‐19: Advocacy for vaccination from a neurological perspective

Sellner, Johann; Jenkins, Thomas M.; Oertzen, Tim J. von; Bassetti, C.; Beghi, Ettore; Bereczki, Dániel; Bodini, Benedetta; Cavallieri, Francesco; Liberto, Giovanni Di; Helbok, Raimund; Macerollo, Antonella; Maia, Luı́s F.; Oreja‐Guevara, Celia; Öztürk, Şerefnur; Rakuša, Martin; Sauerbier, Anna; Soffietti, Riccardo; Taba, Pille; Pisani, Antonio; Priori, Alberto; Zedde, Marialuisa; Crean, Michael; Burlica, Anja; Twardzik, A.; Moro, Elena

doi:10.1111/ene.14713

Cited by 15 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Global vaccination against SARS-CoV-2 in combination with established primary prevention measures to reduce person-to-person transmission will be the critical tool to bring the pandemic under control [64]. Moreover, a vaccine raises legitimate hopes that these depleting therapies, which are categorized as higher efficacy DMDs and are therefore an indispensable tool in the armamentarium for controlling disease activity in MS, can be used more widely before the end of the pandemic.…”

Section: Considerations For Vaccination In the Context Of Immune-depleting Therapiesmentioning

confidence: 99%

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Sellner

2021

Vaccines

Self Cite

View full text Add to dashboard Cite

Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS.

show abstract

Section: Considerations For Vaccination In the Context Of Immune-depleting Therapiesmentioning

confidence: 99%

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Sellner

2021

Vaccines

Self Cite

View full text Add to dashboard Cite

show abstract

“… 56 Patients with Alzheimer disease, Parkinson disease, motor neuron diseases, central nervous system (CNS) disorders, neuromuscular disorders (NMDs), and autoimmune disorders, including multiple sclerosis (MS), myasthenia gravis (MG), and Guillain‐Barré syndrome (GBS), are among the most concerning neurological disorders. 56 Thus, vaccination against Covid‐19 is vital for this population, 57 but vaccination risks and adverse events must be carefully monitored. For example, there is some concern that vaccination against SARS‐CoV‐2 may exacerbate MS by inducing immunological responses and triggering immunological reactions.…”

Section: Neurologic Disordersmentioning

confidence: 99%

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Afshar

Babazadeh

Janbakhsh

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

show abstract

“…[69] There is legitimate hope that a COVID‐19 vaccine will bring the pandemic under control, when combined with appropriate mass testing and existing behavioural and non‐behavioural prevention measures. [70] When it comes to distributing COVID‐19 vaccines,[71] the major challenge will be to prevent the inequality gaps the pandemic has exposed from widening. The decision as to whom to vaccinate first is a complex public health issue.…”

Section: Access To Covid‐19 Diagnostics Vaccination and Therapy: Stopping Inequality Before It Happensmentioning

confidence: 99%

A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: The NeuroCOVID‐19 Task Force of the European Academy of Neurology

Sellner

Jenkins

Oertzen

et al. 2021

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), a multi‐organ disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), continues to challenge health and care systems around the globe. The pandemic has disrupted acute neurology services and routine patient care and has impacted the clinical course in patients with chronic neurological disease. COVID‐19 appears to have exposed inequalities of societies and healthcare systems and had a disproportionate impact on already vulnerable communities. The next challenge will be to set up initiatives to stop disparities in all aspects related to COVID‐19. From the medical perspective, there is a need to consider inequalities in prevention, treatment and long‐term consequences. Some of the issues of direct relevance to neurologists are summarised. With this appraisal, the European Academy of Neurology NeuroCOVID‐19 Task Force intends to raise awareness of the potential impact of COVID‐19 on inequalities in healthcare and calls for action to prevent disparity at individual, national and supranational levels.

show abstract

Primary prevention of COVID‐19: Advocacy for vaccination from a neurological perspective

Cited by 15 publications

References 27 publications

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

A plea for equitable global access to COVID‐19 diagnostics, vaccination and therapy: The NeuroCOVID‐19 Task Force of the European Academy of Neurology

Contact Info

Product

Resources

About